摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-iodo-5-methoxymethoxyanisole | 1089680-12-5

中文名称
——
中文别名
——
英文名称
2-iodo-5-methoxymethoxyanisole
英文别名
1-iodo-2-methoxy-4-(methoxymethoxy)benzene
2-iodo-5-methoxymethoxyanisole化学式
CAS
1089680-12-5
化学式
C9H11IO3
mdl
——
分子量
294.089
InChiKey
TWHTWNQLTGOFKK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    27.7
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    GLUCOCORTICOID RECEPTOR AGONIST COMPRISING NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT
    摘要:
    该对象旨在发现一种新型的药理活性,该活性来自一种新型的1,2,3,4-四氢喹喔啉衍生物,其中含有一个苯基,其上引入了磺酸酯结构。通式(1)表示的化合物或其盐可用作糖皮质激素受体激动剂,特别是作为治疗剂,用于一些被认为对糖皮质激素受体激动剂(例如类固醇)有效的疾病,例如炎症性骨关节疾病,炎症性眼科疾病(眼睛前段或后段的炎症性眼科疾病)。其中,R1表示通式(2a)、(3a)、(4a)或(5a)表示的基团;R2表示可能有取代基的较低烷基基团、可能有取代基的较低环烷基基团等;R3表示较低烷基基团;R4、R5、R6或R7表示卤素原子、可能有取代基的较低烷基基团、羟基、可能有取代基的较低烷氧基团等;m、n、p或q表示0、1或2的数字。
    公开号:
    EP2327699A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    GLUCOCORTICOID RECEPTOR AGONIST COMPRISING NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT
    摘要:
    该对象旨在发现一种新型的药理活性,该活性来自一种新型的1,2,3,4-四氢喹喔啉衍生物,其中含有一个苯基,其上引入了磺酸酯结构。通式(1)表示的化合物或其盐可用作糖皮质激素受体激动剂,特别是作为治疗剂,用于一些被认为对糖皮质激素受体激动剂(例如类固醇)有效的疾病,例如炎症性骨关节疾病,炎症性眼科疾病(眼睛前段或后段的炎症性眼科疾病)。其中,R1表示通式(2a)、(3a)、(4a)或(5a)表示的基团;R2表示可能有取代基的较低烷基基团、可能有取代基的较低环烷基基团等;R3表示较低烷基基团;R4、R5、R6或R7表示卤素原子、可能有取代基的较低烷基基团、羟基、可能有取代基的较低烷氧基团等;m、n、p或q表示0、1或2的数字。
    公开号:
    EP2327699A1
点击查看最新优质反应信息

文献信息

  • GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVES CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT
    申请人:Kato Masatomo
    公开号:US20110166151A1
    公开(公告)日:2011-07-07
    The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye). R 1 represents a group represented by general formula (2a), (3a), (4a) or (5a); R 2 represents a lower alkyl group which may have a substituent, a lower cycloalkyl group which may have a substituent, or the like; R 3 represents a lower alkyl group; R 4 , R 5 , R 6 or R 7 represent a halogen atom, a lower alkyl group which may have a substituent, a hydroxy group, a lower alkoxy group which may have a substituent, or the like; and m, n, p or q represents a number of 0, 1 or 2.
    该对象旨在发现一种新的药理活性,该药理活性是一种含有苯基磺酸酯结构取代基的新型1,2,3,4-四氢喹喔啉生物。由通式(1)或其盐所表示的化合物可用作糖皮质激素受体激动剂,特别是用作糖皮质激素受体激动剂(例如类固醇)被认为对其有效的疾病的治疗剂,如炎症性骨关节疾病,炎症性眼病(眼部前后段的炎症性眼病)。其中,R1表示由通式(2a),(3a),(4a)或(5a)表示的基团;R2表示可以具有取代基的较低烷基基团,可以具有取代基的较低环烷基团或类似基团;R3表示较低烷基基团;R4,R5,R6或R7表示卤素原子,可以具有取代基的较低烷基基团,羟基,可以具有取代基的较低烷氧基或类似基团;m,n,p或q表示0,1或2的数字。
  • NOVEL 1,2,3,4,-TETRAHYDROQUINOXALINE DERIVATIVE WHICH HAS, AS SUBSTITUENT, PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE OR SULFONIC ACID AMIDE STRUCTURE INTRODUCED TEREIN AND HAS GLUCOCORTICOID RECEPTOR-BINDING ACTIVITY
    申请人:Matsuda Mamoru
    公开号:US20100137307A1
    公开(公告)日:2010-06-03
    The compounds represented in general formula (1) or a salt thereof are useful for glucocorticoid receptor modulators. In the formula, R 1 represents a lower alkyl group, a lower cycloalkyl group, an aryl group and the like; R 2 represents a hydrogen atom, a lower alkyl group and the like; R 3 represents a hydrogen atom, a lower alkyl group and the like; R 4 and R 5 represent a hydrogen atom, a lower alkyl group and the like; R 6 represents a hydrogen atom, a lower alkyl group and the like; R 7 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group and the like; W represents an oxygen atom, a sulfur atom, NR 8 and the like; R 8 represents a hydrogen atom, a lower alkyl group and the like; X represents an oxygen atom or a sulfur atom; Y represents a lower alkylene group and the like; Z represents an oxygen atom, a sulfur atom, NR 9 , OCO or OSO 2 ; R 9 represents a hydrogen atom, a lower alkyl group and the like respectively.
    一般式(1)或其盐所代表的化合物可用于糖皮质激素受体调节剂。在该式中,R1代表低碳基,低环烷基,芳基等;R2代表氢原子,低碳基等;R3代表氢原子,低碳基等;R4和R5代表氢原子,低碳基等;R6代表氢原子,低碳基等;R7代表氢原子,低碳基,低烯基等;W代表氧原子,原子,NR8等;R8代表氢原子,低碳基等;X代表氧原子或原子;Y代表低碳基亚烷基等;Z代表氧原子,原子,NR9,OCO或OSO2;R9分别代表氢原子,低碳基等。
  • 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity
    申请人:Santen Pharmaceutical Co., Ltd.
    公开号:US08193187B2
    公开(公告)日:2012-06-05
    The compounds represented in general formula (1) or a salt thereof are useful for glucocorticoid receptor modulators. In the formula, R1 represents a lower alkyl group, a lower cycloalkyl group, an aryl group and the like; R2 represents a hydrogen atom, a lower alkyl group and the like; R3 represents a hydrogen atom, a lower alkyl group and the like; R4 and R5 represent a hydrogen atom, a lower alkyl group and the like; R6 represents a hydrogen atom, a lower alkyl group and the like; R7 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group and the like; W represents an oxygen atom, a sulfur atom, NR8 and the like; R8 represents a hydrogen atom, a lower alkyl group and the like; X represents an oxygen atom or a sulfur atom; Y represents a lower alkylene group and the like; Z represents an oxygen atom, a sulfur atom, NR9, OCO or OSO2; R9 represents a hydrogen atom, a lower alkyl group and the like respectively.
    通式(1)中表示的化合物或其盐对于糖皮质激素受体调节剂是有用的。在该式中,R1表示较低的烷基,较低的环烷基,芳基等;R2表示氢原子,较低的烷基等;R3表示氢原子,较低的烷基等;R4和R5表示氢原子,较低的烷基等;R6表示氢原子,较低的烷基等;R7表示氢原子,较低的烷基,较低的烯基等;W表示氧原子,原子,NR8等;R8表示氢原子,较低的烷基等;X表示氧原子或原子;Y表示较低的烷基等;Z表示氧原子,原子,NR9,OCO或OSO2;R9分别表示氢原子,较低的烷基等。
  • Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent
    申请人:Kato Masatomo
    公开号:US08664221B2
    公开(公告)日:2014-03-04
    The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye). R1 represents a group represented by general formula (2a), (3a), (4a) or (5a); R2 represents a lower alkyl group which may have a substituent, a lower cycloalkyl group which may have a substituent, or the like; R3 represents a lower alkyl group; R4, R5, R6 or R7 represent a halogen atom, a lower alkyl group which may have a substituent, a hydroxy group, a lower alkoxy group which may have a substituent, or the like; and m, n, p or q represents a number of 0, 1 or 2.
    该对象旨在找到一种新型药理活性的新型1,2,3,4-四氢喹喔啉生物,其中包含有一个苯基,其具有引入其中的磺酸酯结构的取代基。由一般式(1)表示的化合物或其盐可用作糖皮质激素受体激动剂,特别是用作治疗糖皮质激素受体激动剂(例如类固醇)被认为对其有效的疾病的治疗剂,如炎性骨/关节疾病,炎性眼病(眼的前段或后段的炎性眼病)。其中,R1表示由一般式(2a),(3a),(4a)或(5a)表示的基团;R2表示可具有取代基的较低烷基基团,可具有取代基的较低环烷基团等;R3表示较低烷基基团;R4、R5、R6或R7表示卤素原子、可具有取代基的较低烷基基团、羟基、可具有取代基的较低烷氧基等;m、n、p或q表示0、1或2的数字。
  • METHOD FOR TREATING AN INFLAMMATORY DISEASE BY ADMINISTERING A 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUND CONTAINING A PHENYL GROUP HAVING A SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS A SUBSTITUENT
    申请人:SANTEN PHARMACEUTICAL CO., LTD.
    公开号:US20140045842A1
    公开(公告)日:2014-02-13
    A method for treating a non-ocular inflammatory disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound represented by the following formula (1) or a salt thereof: R 1 represents: R 2 represents a lower alkyl group, a lower cycloalkyl group or an aralkyl group; R 3 represents a lower alkyl group; R 4 , R 5 , R 6 or R 7 each represents a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a cyano group or a nitro group; m, n, p or q each represents 0, 1 or 2; in the case where m, n, p or q is 2, each of R 4 , R 5 , R 6 or R 7 is the same or different.
    一种治疗非眼部炎症性疾病的方法,包括向需要治疗的患者投与以下式(1)所表示的化合物或其盐的治疗有效量: 其中,R1代表: R2代表较低的烷基、较低的环烷基或芳基烷基; R3代表较低的烷基; R4、R5、R6或R7中的每一个代表卤素原子、较低的烷基、羟基、较低的烷氧基、基或硝基; m、n、p或q中的每一个代表0、1或2; 在m、n、p或q为2的情况下,R4、R5、R6或R7中的每一个相同或不同。
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯